nach oben

Erschienen in:

19.01.2017 | Original Article

Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus

verfasst von: Taís S. Assmann, Guilherme C. K. Duarte, Letícia A. Brondani, Pedro H. O. de Freitas, Égina M. Martins, Luís H. Canani, Daisy Crispim

Erschienen in: Acta Diabetologica | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims

Type 1 diabetes mellitus (T1DM) is characterized by severe autoimmune destruction of pancreatic beta-cells. The triggering of autoimmunity against beta-cells is probably caused by a combination of environmental and genetic risk factors. Even though much is known about the genetic of T1DM, more information is needed to completely unravel this tangled disease. MicroRNAs (miRNAs) are a class of small noncoding RNAs molecules that negatively regulate gene expression by inducing target mRNA cleavage or by inhibiting protein translation. Abnormal miRNA expressions have been described in autoimmune diseases and T1DM. Polymorphisms in genes codifying miRNAs may alter the expression of the corresponding miRNA and, thus, confer susceptibility for a given disease. Therefore, the aim of this study was to investigate whether polymorphisms in genes encoding miR-155, miR-146a, and miR-375 are associated with T1DM.

Methods

Frequencies of the miRNA-146a rs2910164, miRNA-155 rs767649 and miRNA-375 rs6715345 polymorphisms were analyzed in 490 T1DM patients and in 469 nondiabetic subjects.

Results

The miR-146a rs2910164 and miR-155 rs767649 polymorphisms were associated with protection for T1DM, and the strongest association was observed for the dominant model [odds ratio (OR) = 0.557 95% CI 0.355–0.874 and OR = 0.508, 95% CI 0.265–0.973, respectively, after adjustment for age, ethnicity, and risk HLA loci]. However, miR-375 rs6715345 frequencies did not differ between cases and controls.

Conclusion

MiR-146a rs2910164 and miR-155 rs767649 polymorphisms were associated with protection for T1DM.

American Diabetes Association (2015) Classification and diagnosis of diabetes. Diabetes Care 38(Suppl):S8–S16. doi:10.2337/dc15-S005 CrossRef

van Belle TL, Coppieters KT, von Herrath MG (2011) Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91(1):79–118. doi:10.1152/physrev.00003.2010 CrossRefPubMed

Nguyen C, Varney MD, Harrison LC, Morahan G (2013) Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms. Diabetes 62(6):2135–2140. doi:10.2337/db12-1398 CrossRefPubMedPubMedCentral

Pociot F, Lernmark A (2016) Genetic risk factors for type 1 diabetes. Lancet 387(10035):2331–2339. doi:10.1016/S0140-6736(16)30582-7 CrossRefPubMed

Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215–233. doi:10.1016/j.cell.2009.01.002 CrossRefPubMedPubMedCentral

Guay C, Regazzi R (2013) Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 9(9):513–521. doi:10.1038/nrendo.2013.86 CrossRefPubMed

Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105. doi:10.1101/gr.082701.108 CrossRefPubMedPubMedCentral

Butz H, Kinga N, Racz K, Patocs A (2016) Circulating miRNAs as biomarkers for endocrine disorders. J Endocrinol Invest 39(1):1–10. doi:10.1007/s40618-015-0316-5 CrossRefPubMed

Yang M, Ye L, Wang B et al (2015) Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients. J Diabetes 7(2):158–165. doi:10.1111/1753-0407.12163 CrossRefPubMed

10.

Roggli E, Britan A, Gattesco S et al (2010) Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 59(4):978–986. doi:10.2337/db09-0881 CrossRefPubMedPubMedCentral

11.

Churov AV, Oleinik EK, Knip M (2015) MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun Rev 14(11):1029–1037. doi:10.1016/j.autrev.2015.07.005 CrossRefPubMed

12.

Xu WD, Lu MM, Pan HF, Ye DQ (2012) Association of MicroRNA-146a with autoimmune diseases. Inflammation 35(4):1525–1529. doi:10.1007/s10753-012-9467-0 CrossRefPubMed

13.

Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103(33):12481–12486. doi:10.1073/pnas.0605298103 CrossRefPubMedPubMedCentral

14.

O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007) MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104(5):1604–1609. doi:10.1073/pnas.0610731104 CrossRefPubMedPubMedCentral

15.

Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD (2008) MicroRNAs: new regulators of immune cell development and function. Nat Immunol 9(8):839–845. doi:10.1038/ni.f.209 CrossRefPubMed

16.

Faraoni I, Antonetti FR, Cardone J, Bonmassar E (2009) miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 1792(6):497–505. doi:10.1016/j.bbadis.2009.02.013 CrossRefPubMed

17.

Rusca N, Monticelli S (2011) MiR-146a in Immunity and Disease. Mol Biol Int 2011:437301. doi:10.4061/2011/437301 CrossRefPubMedPubMedCentral

18.

Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R (2011) Diabetes mellitus, a microRNA-related disease? J Lab Clin Med 157(4):253–264. doi:10.1016/j.trsl.2011.01.009 CrossRef

19.

Li X (2014) MiR-375, a microRNA related to diabetes. Gene 533(1):1–4. doi:10.1016/j.gene.2013.09.105 CrossRefPubMed

20.

Erener S, Mojibian M, Fox JK, Denroche HC, Kieffer TJ (2013) Circulating miR-375 as a biomarker of β-cell death and diabetes in mice. Endocrinology 154(2):603–608. doi:10.1210/en.2012-1744 CrossRefPubMed

21.

Marchand L, Jalabert A, Meugnier E et al (2016) miRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes. J Diabetes Res 2016:1869082. doi:10.1155/2016/1869082 CrossRefPubMedPubMedCentral

22.

Nielsen LB, Wang C, Sorensen K et al (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362. doi:10.1155/2012/896362 CrossRefPubMedPubMedCentral

23.

Khamaneh AM, Alipour MR, Sheikhzadeh Hesari F, Ghadiri Soufi F (2015) A signature of microRNA-155 in the pathogenesis of diabetic complications. J Physiol Biochem 71(2):301–309. doi:10.1007/s13105-015-0413-0 CrossRefPubMed

24.

Cammaerts S, Strazisar M, De Rijk P, Del Favero J (2015) Genetic variants in microRNA genes: impact on microRNA expression, function, and disease. Front Genet 6:186. doi:10.3389/fgene.2015.00186 CrossRefPubMedPubMedCentral

25.

Li C, Fu W, Zhang Y et al (2015) Meta-analysis of microRNA-146a rs2910164 G > C polymorphism association with autoimmune diseases susceptibility, an update based on 24 studies. PLoS ONE 10(4):e0121918. doi:10.1371/journal.pone.0121918 CrossRefPubMedPubMedCentral

26.

Park R, Lee WJ, Ji JD (2016) Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: a meta-analysis. Autoimmunity. doi:10.3109/08916934.2016.1171854 CrossRefPubMed

27.

Jimenez-Morales S, Gamboa-Becerra R, Baca V et al (2012) MiR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients. Tissue Antigens 80(4):317–321. doi:10.1111/j.1399-0039.2012.01929.x CrossRefPubMed

28.

von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349. doi:10.1016/j.jclinepi.2007.11.008 CrossRef

29.

Little J, Higgins JP, Ioannidis JP et al (2009) Strengthening the reporting of genetic association studies (STREGA)—an extension of the STROBE statement. Genet Epidemiol 33(7):581–598. doi:10.1002/gepi.20410 CrossRefPubMed

30.

Assmann TS, Brondani Lde A, Bauer AC, Canani LH, Crispim D (2014) Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus. Eur J Endocrinol 170(4):519–527. doi:10.1530/EJE-13-0963 CrossRefPubMed

31.

Gong J, Tong Y, Zhang HM et al (2012) Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 33(1):254–263. doi:10.1002/humu.21641 CrossRefPubMed

32.

Hsu SD, Chu CH, Tsou AP et al (2008) miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36(Database issue):D165–169. doi:10.1093/nar/gkm1012 CrossRefPubMed

33.

Kaidonis G, Gillies MC, Abhary S et al (2016) A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetol. doi:10.1007/s00592-016-0850-4 CrossRefPubMed

34.

Ciccacci C, Morganti R, Di Fusco D et al (2014) Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes. Acta Diabetol 51(4):663–671. doi:10.1007/s00592-014-0582-2 CrossRefPubMed

35.

Xie K, Ma H, Liang C et al (2015) A functional variant in miR-155 regulation region contributes to lung cancer risk and survival. Oncotarget 6(40):42781–42792. doi:10.18632/oncotarget.5840 CrossRefPubMedPubMedCentral

36.

Bulik-Sullivan B, Selitsky S, Sethupathy P (2013) Prioritization of genetic variants in the microRNA regulome as functional candidates in genome-wide association studies. Hum Mutat 34(8):1049–1056. doi:10.1002/humu.22337 CrossRefPubMedPubMedCentral

37.

Nahid MA, Pauley KM, Satoh M, Chan EK (2009) miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem 284(50):34590–34599. doi:10.1074/jbc.M109.056317 CrossRefPubMedPubMedCentral

38.

Nahid MA, Satoh M, Chan EK (2011) MicroRNA in TLR signaling and endotoxin tolerance. Cell Mol Immunol 8(5):388–403. doi:10.1038/cmi.2011.26 CrossRefPubMedPubMedCentral

39.

Nahid MA, Satoh M, Chan EK (2011) Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. Open J Immunol 186(3):1723–1734. doi:10.4049/jimmunol.1002311 CrossRef

40.

Doxaki C, Kampranis SC, Eliopoulos AG, Spilianakis C, Tsatsanis C (2015) Coordinated Regulation of miR-155 and miR-146a Genes during Induction of Endotoxin Tolerance in Macrophages. J Immunol 195(12):5750–5761. doi:10.4049/jimmunol.1500615 CrossRefPubMed

41.

Gao M, Wang X, Zhang X et al (2015) Attenuation of cardiac dysfunction in polymicrobial sepsis by microRNA-146a is mediated via targeting of IRAK1 and TRAF6 expression. J Immunol 195(2):672–682. doi:10.4049/jimmunol.1403155 CrossRefPubMed

42.

Saba R, Sorensen DL, Booth SA (2014) MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol 5:578. doi:10.3389/fimmu.2014.00578 CrossRefPubMedPubMedCentral

43.

Meisgen F, Xu Landen N, Wang A et al (2014) MiR-146a negatively regulates TLR2-induced inflammatory responses in keratinocytes. J Invest Dermatol 134(7):1931–1940. doi:10.1038/jid.2014.89 CrossRefPubMed

44.

Al-Quraishy S, Dkhil MA, Delic D, Abdel-Baki AA, Wunderlich F (2012) Organ-specific testosterone-insensitive response of miRNA expression of C57BL/6 mice to Plasmodium chabaudi malaria. Parasitol Res 111(3):1093–1101. doi:10.1007/s00436-012-2937-3 CrossRefPubMed

45.

Nakasa T, Miyaki S, Okubo A et al (2008) Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Semin Arthritis Rheum 58(5):1284–1292. doi:10.1002/art.23429 CrossRef

46.

Lu LF, Boldin MP, Chaudhry A et al (2010) Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 142(6):914–929. doi:10.1016/j.cell.2010.08.012 CrossRefPubMedPubMedCentral

47.

Curtale G, Citarella F, Carissimi C et al (2010) An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood 115(2):265–273. doi:10.1182/blood-2009-06-225987 CrossRefPubMed

48.

Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci USA 105(20):7269–7274. doi:10.1073/pnas.0802682105 CrossRefPubMedPubMedCentral

49.

Xu T, Zhu Y, Wei QK et al (2008) A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29(11):2126–2131. doi:10.1093/carcin/bgn195 CrossRefPubMed

50.

Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H (2008) A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 29(10):1963–1966. doi:10.1093/carcin/bgn172 CrossRefPubMed

51.

Ma X, Becker Buscaglia LE, Barker JR, Li Y (2011) MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 3(3):159–166. doi:10.1093/jmcb/mjr007 CrossRefPubMedPubMedCentral

52.

Sun Y, Cai J, Ma F, Lu P, Huang H, Zhou J (2012) miR-155 mediates suppressive effect of progesterone on TLR3, TLR4-triggered immune response. Immunol Lett 146(1–2):25–30. doi:10.1016/j.imlet.2012.04.007 CrossRefPubMed

53.

Wang P, Hou J, Lin L et al (2010) Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 185(10):6226–6233. doi:10.4049/jimmunol.1000491 CrossRefPubMed

54.

Pareek S, Roy S, Kumari B, Jain P, Banerjee A, Vrati S (2014) MiR-155 induction in microglial cells suppresses Japanese encephalitis virus replication and negatively modulates innate immune responses. J Neuroinflammation 11:97. doi:10.1186/1742-2094-11-97 CrossRefPubMedPubMedCentral

55.

Curtis AM, Fagundes CT, Yang G et al (2015) Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. Proc Natl Acad Sci USA 112(23):7231–7236. doi:10.1073/pnas.1501327112 CrossRefPubMedPubMedCentral

56.

Schulte LN, Westermann AJ, Vogel J (2013) Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res 41(1):542–553. doi:10.1093/nar/gks1030 CrossRefPubMed

57.

Karczewski KJ, Tatonetti NP, Landt SG et al (2011) Cooperative transcription factor associations discovered using regulatory variation. Proc Natl Acad Sci USA 108(32):13353–13358. doi:10.1073/pnas.1103105108 CrossRefPubMedPubMedCentral

58.

Ji J, Xu M, Tu J et al (2016) MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of Hepatocellular carcinoma. Oncotarget. doi:10.18632/oncotarget.11206 CrossRefPubMedPubMedCentral

59.

Poy MN, Hausser J, Trajkovski M et al (2009) miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci USA 106(14):5813–5818. doi:10.1073/pnas.0810550106 CrossRefPubMedPubMedCentral

60.

Erener S, Mojibian M, Fox JK, Denroche HC, Kieffer TJ (2013) Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 154(2):603–608. doi:10.1210/en.2012-1744 CrossRefPubMed

61.

Zhu J, Yang L, You W et al (2015) Genetic variation in miR-100 rs1834306 is associated with decreased risk for esophageal squamous cell carcinoma in Kazakh patients in northwest China. Int J Clin Exp Pathol 8(6):7332–7340PubMedPubMedCentral

62.

El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E (2008) miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 57(10):2708–2717. doi:10.2337/db07-1614 CrossRefPubMedPubMedCentral

63.

Poy MN, Eliasson L, Krutzfeldt J et al (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432(7014):226–230. doi:10.1038/nature03076 CrossRefPubMed

Titel: Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus
verfasst von: Taís S. Assmann
Guilherme C. K. Duarte
Letícia A. Brondani
Pedro H. O. de Freitas
Égina M. Martins
Luís H. Canani
Daisy Crispim
Publikationsdatum: 19.01.2017
Verlag: Springer Milan
Erschienen in: Acta Diabetologica / Ausgabe 5/2017
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-016-0961-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus

Abstract

Aims

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Treatment of diabetic gastroparesis with botulinum toxin injection guided by endoscopic ultrasound in a patient with type 1 diabetes: the first report

Cognitive impairment and dementia: a new emerging complication of type 2 diabetes—The diabetologist’s perspective

Investigation of the relationship between hemoglobin and serum iron levels and early-phase insulin secretion in non-diabetic subjects: statistical and methodological issues

Lipoprotein (a) is not significantly associated with type 2 diabetes mellitus: cross-sectional study of 1604 cases and 7983 controls

Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes

Bone health in subjects with type 1 diabetes for more than 50 years

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin